74PD - When is a pathological diagnosis preferred before stereotactic ablative radiotherapy (SABR) for stage I lung cancer? A decision analysis
|Date||27 March 2014|
|Session||Poster Discussion 1|
|Topics|| Non-Small-Cell Lung Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A.V. Louie1, M.G. Hunink2, P. Patel3, B.S. Ferket2, F.J. Lagerwaard1, G.B. Rodrigues4, J.K. Salama3, C. Kelsey3, D.A. Palma4, S. Senan5
In unfit patients who are at increased risk for complications from a biopsy, SABR for a solitary pulmonary nodule (SPN) is acceptable after review by a multidisciplinary tumor board [ESMO recommendations 2013]. We performed a decision analysis that can be employed to inform the appropriate lung cancer prevalence threshold of when this strategy is warranted.